Articles

Videos

Podcasts

Clinical

Generic small molecule drugs take advantage of abbreviated approval pathways and have markedly lower development costs compared to their reference products. 

The Promise & Pressures of Biologics R&D

Presenters at the AMCP Nexus conference explore outcomes data and whether these medications should be substituted for reference products more frequently.

Clinical Results Support Greater Use of Oncology Biosimilars

Bevacizumab-adcd (Vegzelma) is indicated for the treatment of nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic colorectal cancer; persistent, recurrent, or metastatic cervical cancer; metastatic renal cell carcinoma; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

FDA Approves Bevacizumab Biosimilar for Six Types of Cancer

The biosimilar matches Prolia in efficacy, immunogenicity, pharmacodynamics, and pharmacokinetics in women who are postmenopausal with osteoporosis.

Sandoz’s Denosumab Meets Primary Endpoints in Phase 3 Trial 

The long-acting, once-daily hormone controls high blood sugar in individuals aged 1 year or older with diabetes.

Novo Nordisk Launches Tresiba Biologic Analog Insulin to Expand Affordability Options 

Pharmacy Times spoke with Carina Dolan, PharmD, Editor in Chief of the Pharmacy Market Outlook, about the highlights and the big picture moving forward for hospitals and health systems.

The Big Picture Moving Forward as a Hospital, Health System

The biosimilar is expected to be launched as a prefilled syringe in early 2023.

FDA Approves Stimufend, Biosimilar for Pegfilgrastim-fpgk

The 2022 Biosimilar Survey signaled that most pharmacists are willing to incorporate biosimilars into their formularies, but certain factors are preventing widespread adoption.

Survey Finds Biosimilars Could Become More Frequently Adopted into Formulary Lists

Paul Forsberg, PharmD, BCOP, MHA, director of Pharmacy Services at Minnesota Oncology discusses how pharmacists can remain on top of shifts in the nature of biosimilar payer benefit design.

Expert Discusses Role of Pharmacist in Oncology Practices, Biosimilars

Study evaluates efficacy, immunogenicity, safety of the product to eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

Amgen Announces Positive Data for ABP959, Biosimilar Candidate to Soliris

® Biosimilars Resource Center is a comprehensive resource for clinical news and expert insights on issues related to biosimilar drugs, a biological product that is highly similar to a reference biologic for which there are no clinically meaningful differences in terms of safety, purity, and efficacy.